Mutation Burden Predictive of First-Line Immunotherapy Response in NSCLC – Targeted Oncology
Targeted Oncology |
Mutation Burden Predictive of First-Line Immunotherapy Response in NSCLC
Targeted Oncology In an updated analysis of CheckMate-586, investigators found that tumor mutational burden (TMB) identified patients with non–small cell lung cancer (NSCLC) who were more likely to respond to first-line combination immunotherapy with nivolumab (Opdivo … Immunotherapy superior to chemotherapy for advanced lung cancer … |
